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The field of interventional cardiology has made significant progress over the past three 
decades in the management of patients with ST-segment elevation myocardial infarction 
(STEMI), with the introduction of thrombolysis and primary percutaneous coronary 
intervention as the mainstay treatment. Consequently, this has led to a significant reduction 
in morbidity and mortality in these patients.1 However, despite these advances, in-hospital 
mortality remains high at approximately 5-6%, increasing to 7-18% at one year.2 This is 
partly due to the myocardial injury and cardiomyocyte death, which paradoxically occurs 
despite achieving patency of the infarct-related epicardial coronary artery – termed 
‘myocardial reperfusion injury’. Four types of myocardial reperfusion injury have been 
described, namely reperfusion-induced arrhythmias, myocardial stunning, microvascular 
obstruction (MVO) and lethal myocardial reperfusion injury.3 The former two are self-
limiting and reversible. The latter two are irreversible and induce cardiomyocyte death and 
have been the focus of intense research over the past three decades. Crucially, there 
currently exists no effective therapy for preventing these lethal forms of myocardial 
reperfusion injury. 
 
MVO, which manifests clinically as coronary no-reflow in the infarct-related artery 
following primary percutaneous coronary intervention, has been defined as the “inability 
to reperfuse a previously ischaemic region”.4 In a recent meta-analysis using patient-level 
data of more than 1000 patients, MVO by cardiovascular magnetic resonance imaging was 
found to be present in 54.9% of primary percutaneous coronary intervention patients 
despite the presence of normal coronary flow within the infarct-related artery post- 
primary percutaneous coronary intervention.5 This study concluded that MVO was an 
independent predictor of major adverse cardiovascular events and cardiac death, whereas 
infarct size as a percentage of the left ventricle was not independently associated with 
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major adverse cardiovascular events.5 Therefore, there is a pressing need to investigate 
MVO as a therapeutic target for studies targeting reperfusion injury in STEMI patients. 
 
The animal model of acute myocardial ischemia-reperfusion injury remains a fundamental 
research tool necessary for the translation of basic science knowledge into the clinical 
setting. The porcine heart has similar anatomic and haemodynamic resemblance to the 
human heart6 and therefore has become the preferred model in cardiovascular research.  
 
In the article published in Revista Española de Cardiología, Hervas et al7 investigate the 
dynamics of MVO in the porcine heart using intracoronary Thioflavin-S (T-S). The main 
objectives of their study were 2-fold. Firstly, they wanted to provide evidence for the pre-
requisite of acute ischemia-reperfusion injury for the development of MVO and its 
temporal evolution. Secondly, they aimed to compare the intra-coronary administration of 
T-S against two other conventional routes of administration of T-S (intra-ventricular and 
intra-aortic) to visual MVO. They used a porcine model of acute myocardial infarction by 
inflating an angioplasty balloon in the mid-left anterior descending coronary artery for 90 
minutes followed by reperfusion. Intra-coronary T-S solution was selectively infused into 
the proximal left anterior descending through a catheter at 1-minute, 1-week, and 1-month 
post-reperfusion. In the no-reperfusion group, an over-the-wire balloon was used and was 
left inflated after 90 minutes. The T-S was then injected through the lumen of the over-
the-wire balloon. In the control group, the angioplasty balloon was not inflated. Hearts 
were then arrested and excised for histological evaluation (visualization of T-S staining 
under fluorescent light for MVO and staining with 2,3,5-triphenyltetrazolium chloride for 
infarct size). The second part of their experiment was intra-aortic and intra-ventricular 
injection of T-S at one week following the same ischemia-reperfusion protocol. The main 
findings of their study were: (1) MVO, defined as absence of T-S stain, occurred in all the 
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reperfused hearts and as early as 1 minute after reperfusion, whereas none of the hearts in 
the non-reperfused group had MVO. The extent of MVO was largest in the 1-week 
reperfusion group and smallest in the 1-month reperfusion group; (2) the signal intensity 
ratio between the areas of MVO and non-MVO in the reperfused territory was higher in 
the intra-coronary group compared to the intra-aortic and intra-ventricular groups, 
providing better differentiation of MVO. The authors concluded that myocardial 
reperfusion plays a critical role in the development of MVO and hence the importance of 
this critical window in STEMI patients. Secondly, the intra-coronary route for T-S 
administration allowed accurate characterization of MVO when compared to the 
conventional intra-aortic and intra-ventricular routes of administration.  
 
Hervas et al7 should be congratulated for their study which provides interesting insights 
into the pathophysiology of MVO in the reperfused heart. Firstly, their study reinforces 
the fact that MVO is a consequence of myocardial reperfusion injury and therefore any 
future studies targeting the reduction of MVO should be initiated prior to reperfusion of 
the infarct-related artery in order to gain maximum cardioprotection. Khan et al8 recently 
reported in a cohort of 94 STEMI patients (21 presented late and had no reperfusion 
therapy) that MVO by cardiovascular magnetic resonance imaging was not exclusive to 
reperfusion therapy and was primarily related to duration of ischemia. However, coronary 
angiography was performed in only 15 of those patients and 2 patients had Thrombolysis 
in Myocardial Infarction (TIMI) flow 2 and 4 patients had TIMI flow 1 on the diagnostic 
images. It is highly likely that some of these patients already had intermittent reperfusion 
and ischemia and given the significant number of patients having some form of 
spontaneous reperfusion with TIMI flow > 0, this would explain the occurrence of MVO 
in these patients. 
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 T-S is a fluorescent dye used to assess the patency of the microvascular circulation by 
staining endothelial cells in patent vessels during reperfusion.9 Although Hervas et al7 
showed that MVO by T-S staining occur as early as one minute after reperfusion, their 
study would have been more robust if they were able to use a second parameter such as 
carbon black and microspheres10 or electron microscopy of the microvasculature and tissue 
characterization by cardiac magnetic resonance imaging to further characterize the areas 
of MVO.  
 
Hervas et al7 also attempted to provide some insight into the temporal evolution of MVO 
at 1 minute, 1 week and 1 month post reperfusion. Rochitte et al11 had previously shown 
that the extent of MVO increased significantly over the first 48 hours following 
reperfusion in a canine model. Orn et al12 have shown a higher prevalence of MVO by 
cardiovascular magnetic resonance imaging at 2 days than at 1 week in STEMI patients. 
Furthermore, a recent abstract by Carrick et al13 reported on serial scanning in 30 STEMI 
patients at 4 time points (4–12 hours, 3 days, 10 days and 6–7 months post reperfusion). 
The amount of MVO was greatest at 4–12 hours and fell progressively over time and the 
amount of intramyocardial hemorrhage increased from 4–12 hours and peaked 3 days. 
Therefore, the observation from this study that MVO reached its largest extent at 1 week 
is not accurate and additional time-points between 1-minute and 1-week would have 
provided a more accurate evolution of MVO. 
 
T-S has always been predominantly administered via the intravenous, intra-atrial, intra-
aortic or intra-ventricular route. However, the same group has already previously used 
intracoronary T-S administration in previous studies14,15 but in this study provided direct 
comparison of the signal intensities for MVO detection when compared to the intra-aortic 
and intra-ventricular routes of administration. The intra-coronary route offered better 
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definition between MVO and the reperfused tissue and this will no doubt be a valuable 
technique for future research studies on MVO. 
 
Despite its limitations, this study by Hervas et al7 provides a platform for future research 
in this field. Although we know that MVO portends to poor prognosis,5 little is known 
about the ideal timing for MVO imaging and the extent of MVO which best predicts 
outcome, and more work needs to be done on developing strategies to minimize MVO 
and translating them to clinical practice to eventually improve outcome in these patients. 
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